This week’s signal isn’t one trial readout, it’s the sector’s plumbing maturing on two fronts at once. Telix installs a permanent Chair, Ratio Therapeutics and Radiopharm Theranostics both land fresh capital, and Curium stakes its manufacturing scale on becoming a genuine Pluvicto rival. Meanwhile three new studies converge on the same practical question: how much lutetium is actually enough, and does the specific ligand matter?

Curium is positioning itself as a real challenger to Pluvicto, arguing that its in-house lutetium manufacturing and distribution network can deliver the supply-chain resiliency the RLT field currently lacks. Lantheus had already shelved its own PSMA-directed filing before agreeing to merge with Curium in an up-to-$8 billion transaction, leaving Curium as the best-positioned company to launch a direct rival to Pluvicto. Curium says it will lean on decades of radiopharmaceutical manufacturing experience, in-house lutetium production lines, and established nuclear medicine relationships as it heads toward an FDA filing for its own 177Lu-PSMA-I&T therapy.

A newly published Phase 2 protocol will randomize 120 mCRPC patients 2:1 to a dose-intensified induction-then-maintenance regimen versus standard every-6-week dosing of 177Lu-PSMA-597, with a 90%-or-greater PSA decline as the primary endpoint (OPTIMAL-PSMA).

A RESIST-PC Phase 2 dosimetry substudy comparing 6.0 and 7.4 GBq cycles of 177Lu-PSMA-617 found no significant difference in kidney, salivary gland, or liver absorbed dose between arms, though tumor dose varied widely on an inter- and intrapatient level regardless of injected activity. Previously discussed in Issue 3; revisited here for the normal-organ dose finding.

A propensity-matched real-world analysis of 140 mCRPC patients found no statistically significant overall survival difference between 177Lu-PSMA-617 and 177Lu-PSMA-I&T, despite higher cumulative administered activity and better PSA response rates with 617 — a reminder that more activity doesn’t automatically translate to a better outcome. Published July 2; flagged here as slightly older than our usual window but not previously covered in this newsletter.

Ratio Therapeutics closed a $70 million Series C on July 31, with participation from Bristol Myers Squibb, Eli Lilly, and Catalio Capital Management, bringing total capital raised past $240 million. The funds advance Ratio’s Ac-225 ATLAS study and a next-generation radioligand candidate toward the clinic.

Radiopharm Theranostics will hold an extraordinary general meeting on or about September 11 seeking shareholder approval for a combined US$4.1 million registered direct offering and up to A$12.7 million in Australian placement and share purchase plan proceeds, earmarked chiefly for the company’s planned RAD101 registrational study.

Telix Pharmaceuticals named David Gill as Chair of the Board, effective September 1, succeeding Dr. Mark Nelson, who remains on the board as a Non-Executive Director. Gill joined Telix as a director in May as part of planned board succession and brings more than 35 years of biopharmaceutical and radiopharmaceutical leadership experience.